FDA Announces Potential Safety Issues With Endo Pain Drugs Made by Novartis

The Food and Drug Administration Jan. 9 announced a potential problem with opiate pain medications manufactured and packaged for Endo Pharmaceuticals by Novartis Consumer Health at its Lincoln, Neb., manufacturing site.

Due to problems that occurred when these products were packaged and labeled at the site, tablets from one product type may have carried over into packaging of another product, the agency said. This could result in a stray pill of one medicine ending up in the bottle of another product.

Novartis said in a press release that it has voluntarily suspended operations at the Lincoln facility to accelerate maintenance ...